Use of treatment algorithms for depression

Journal of Clinical Psychiatry

Volumn 67, Issue 9, 2006, Pages 1458-1465

  Trivedi, Madhukar H ^a   Fava, Maurizio ^b   Marangell, Lauren B ^c   Osser, David N ^b   Shelton, Richard C ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BAYLOR COLLEGE OF MEDICINE   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; DESIPRAMINE; ESZOPICLONE; FLUOXETINE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ALGORITHM; ATTENTION; DEPRESSION; ELECTROCONVULSIVE THERAPY; HUMAN; MONOTHERAPY; NOTE; PATIENT CARE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE STIMULATION;

EID: 33750061600     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/jcp.v67n0919     Document Type: Note

References (25)

1. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006;163:28-40
2. Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. Arch Gen Psychiatry 2004;61:669-680
3. Katon W, Von Korff M, Lin E, et al. Collaborative management to achieve treatment guidelines: impact on depression in primary care. JAMA 1995;273:1026-1031
4. Unützer J, Rubenstein L, Katon WJ, et al. Two-year effects of quality improvement programs on medication management for depression. Arch Gen Psychiatry 2001;58:935-942
5. Crismon ML, Trivedi MH, Pigott TA, et al. The Texas Medication Algorithm Project: report of the Texas consensus conference panel on medication treatment of major depressive disorder. J Clin Psychiatry 1999;60:142-156
6. Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006;354:1243-1252
7. Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion SR, sertraline, or venlafaxine XR after failure of SSRIs for depression. N Engl J Med 2006;354:1231-1242
8. Rush AJ, Trivedi M, Fava M. Depression, IV: STAR*D treatment trial for depression. Am J Psychiatry 2003;160:237
9. Quitkin FM, McGrath PJ, Stewart JW, et al. Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. J Clin Psychiatry 2005;66:670-676
10. Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. J Clin Psychopharmacol 2005;25:336-341
11. Paykel ES, Ramana R, Cooper Z, et al. Residual symptoms after partial remission: an important outcome in depression. Psychol Med 1995;25:1171-1180
12. Thase ME, Simons AD, McGeary J, et al. Relapse after cognitive behavioral therapy of depression: potential implications for longer courses of treatment. Am J Psychiatry 1992;149:1046-1052
13. Tomarken AJ, Dichter GS, Freid C, et al. Assessing the effects of bupropion SR on mood dimensions of depression. J Affect Disord 2004;78:235-241
14. Joffe RT, Levitt AJ, Sokolov ST, et al. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-115
15. Fava M, Dunner DL, Greist JH, et al. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial. J Clin Psychiatry 2001;62:413-420
16. Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder Biol Psychiatry 2006;59:1052-1060
17. Nelson J, Mazure C, Jatlow P, et al. Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 2004;55:296-300
18. Fava M, Rosenbaum JF, McGrath PJ, et al. Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994;151:1372-1374
19. Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in parial responders and nonresponders to fluoxetine. J Clin Psychopharmacol 2002;22:379-387
20. Nierenberg AA, Papakostas GI, Petersen T, et al. Lithium augmentation of nortriptyline for subjects resistant to multiple antidepressants. J Clin Psychopharmacol 2003;23:92-95
21. Nelson JC, Mazure CM, Bowers MB Jr, et al. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991;48:303-307
22. Papakostas GI. Augmentation of standard antidepressants with aytpical antipsychotic agents for treatment-resistant major depressive disorder. Essent Psychophramacol 2005;6:209-220
23. Cooper WO, Hickson GB, Fuchs C, et al. New users of antipsychotic medications among children enrolled in TennCare. Arch Pediatr Adolesc Med 2004;158:753-759
24. Marangell LB, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry 2002;51:280-287
25. Hollon SD, DeRubeis RJ, Shelton RC, et al. Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 2005;62:417-422